2013 Q1 Form 10-K Financial Statement
#000148381313000033 Filed on March 01, 2013
Income Statement
| Concept | 2013 Q1 | 2012 Q4 | 2012 |
|---|---|---|---|
| Revenue | $11.83M | $21.79M | $42.33M |
| YoY Change | 59.04% | 803.86% | -24.54% |
| Cost Of Revenue | $739.0K | $700.0K | $1.094M |
| YoY Change | 944.36% | 600.0% | 324.3% |
| Gross Profit | $769.0K | $805.9K | $41.23M |
| YoY Change | 559.24% | -66.42% | -26.15% |
| Gross Profit Margin | 6.5% | 3.7% | 97.42% |
| Selling, General & Admin | $7.556M | $7.000M | $24.81M |
| YoY Change | 14.16% | 18.64% | 37.05% |
| % of Gross Profit | 982.57% | 868.65% | 60.18% |
| Research & Development | $22.03M | $18.60M | $70.04M |
| YoY Change | 38.66% | 24.83% | 21.68% |
| % of Gross Profit | 2865.28% | 2308.12% | 169.88% |
| Depreciation & Amortization | $295.0K | $300.0K | $1.079M |
| YoY Change | 24.06% | 50.0% | -1.54% |
| % of Gross Profit | 38.36% | 37.23% | 2.62% |
| Operating Expenses | $29.59M | $25.50M | $94.86M |
| YoY Change | 31.45% | 23.19% | 25.36% |
| Operating Profit | -$18.50M | -$24.69M | -$53.63M |
| YoY Change | 22.16% | 34.94% | 170.3% |
| Interest Expense | $848.0K | $0.00 | $0.00 |
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $55.00K | $73.44K | |
| YoY Change | 159.23% | 6.3% | |
| Pretax Income | -$19.30M | -$4.400M | -$53.60M |
| YoY Change | 27.81% | -76.09% | 170.71% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$19.29M | -$4.406M | -$53.55M |
| YoY Change | 27.58% | -76.08% | 170.88% |
| Net Earnings / Revenue | -163.01% | -20.22% | -126.53% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$171.7K | -$39.15K | -$482.4K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 113.1M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2013 Q1 | 2012 Q4 | 2012 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $87.43M | $99.50M | $99.50M |
| YoY Change | -25.02% | 88.45% | 88.45% |
| Cash & Equivalents | $39.02M | $99.50M | $99.50M |
| Short-Term Investments | $48.41M | $0.00 | $0.00 |
| Other Short-Term Assets | $10.60M | $12.80M | $12.80M |
| YoY Change | 19.1% | 54.22% | 54.22% |
| Inventory | $2.737M | $2.671M | $2.700M |
| Prepaid Expenses | |||
| Receivables | $10.38M | $15.70M | $15.70M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $111.1M | $130.6M | $130.6M |
| YoY Change | -16.21% | 104.15% | 104.06% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.975M | $3.700M | $3.700M |
| YoY Change | 80.68% | 108.94% | 105.56% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.800M | $400.0K | $400.0K |
| YoY Change | |||
| Total Long-Term Assets | $5.756M | $4.100M | $4.100M |
| YoY Change | 174.09% | 131.53% | 127.78% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $111.1M | $130.6M | $130.6M |
| Total Long-Term Assets | $5.756M | $4.100M | $4.100M |
| Total Assets | $116.9M | $134.7M | $134.7M |
| YoY Change | -13.24% | 104.88% | 104.71% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.885M | $2.272M | $2.300M |
| YoY Change | -3.84% | -69.94% | -69.74% |
| Accrued Expenses | $9.178M | $7.783M | $7.800M |
| YoY Change | 27.47% | 38.6% | 39.29% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $1.362M | $0.00 | $0.00 |
| YoY Change | |||
| Total Short-Term Liabilities | $19.75M | $18.95M | $18.90M |
| YoY Change | 18.27% | 9.5% | 9.25% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $29.80M | $29.66M | $31.10M |
| YoY Change | |||
| Other Long-Term Liabilities | $436.8K | $0.00 | $35.80M |
| YoY Change | -98.82% | -100.0% | -4.79% |
| Total Long-Term Liabilities | $436.8K | $29.66M | $66.90M |
| YoY Change | -98.82% | -21.11% | 77.93% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $19.75M | $18.95M | $18.90M |
| Total Long-Term Liabilities | $436.8K | $29.66M | $66.90M |
| Total Liabilities | $20.19M | $48.61M | $85.90M |
| YoY Change | -62.41% | -11.46% | 56.47% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$317.9M | -$298.6M | |
| YoY Change | 21.86% | ||
| Common Stock | $349.6M | $347.4M | |
| YoY Change | 35.76% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $31.68M | $48.86M | $48.90M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $116.9M | $134.7M | $134.7M |
| YoY Change | -13.24% | 104.88% | 104.71% |
Cashflow Statement
| Concept | 2013 Q1 | 2012 Q4 | 2012 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$19.29M | -$4.406M | -$53.55M |
| YoY Change | 27.58% | -76.08% | 170.88% |
| Depreciation, Depletion And Amortization | $295.0K | $300.0K | $1.079M |
| YoY Change | 24.06% | 50.0% | -1.54% |
| Cash From Operating Activities | -$10.75M | -$16.90M | -$64.28M |
| YoY Change | -44.47% | 25.19% | 87.4% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $534.0K | -$500.0K | $1.413M |
| YoY Change | 0.0% | 70.55% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$48.90M | ||
| YoY Change | |||
| Cash From Investing Activities | -$49.48M | -$500.0K | -$1.413M |
| YoY Change | -312401.19% | 0.0% | 70.55% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | $81.48M | |
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -$252.0K | 29.70M | $112.8M |
| YoY Change | -100.3% | 4850.0% | 2275.81% |
| NET CHANGE | |||
| Cash From Operating Activities | -$10.75M | -16.90M | -$64.28M |
| Cash From Investing Activities | -$49.48M | -500.0K | -$1.413M |
| Cash From Financing Activities | -$252.0K | 29.70M | $112.8M |
| Net Change In Cash | -$60.48M | 12.30M | $47.13M |
| YoY Change | -194.83% | -191.79% | -255.12% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$10.75M | -$16.90M | -$64.28M |
| Capital Expenditures | $534.0K | -$500.0K | $1.413M |
| Free Cash Flow | -$11.28M | -$16.40M | -$65.69M |
| YoY Change | -41.71% | 26.15% | 87.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7556859 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2271689 | USD |
| CY2011Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2262465 | USD |
| CY2012Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15703087 | USD |
| CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7783447 | USD |
| CY2011Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5615574 | USD |
| CY2011Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5745903 | USD |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6680627 | USD |
| CY2011Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
255817772 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
347314658 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5569899 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8348587 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4866325 | USD |
| CY2010 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4866325 | USD |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5569899 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8348587 | USD |
| CY2012Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | USD |
| CY2011Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | USD |
| CY2011 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6365667 | shares |
| CY2012 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7444333 | shares |
| CY2010 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8095365 | shares |
| CY2012Q4 | us-gaap |
Assets
Assets
|
134728397 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
65758545 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
131027935 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
63987497 | USD |
| CY2011 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
189898 | USD |
| CY2012 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
153623 | USD |
| CY2010 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
13806 | USD |
| CY2011 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
0 | USD |
| CY2012 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
1450000 | USD |
| CY2010 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
0 | USD |
| CY2011Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
0 | USD |
| CY2012Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
1450000 | USD |
| CY2012Q4 | us-gaap |
Capital Leased Assets Gross
CapitalLeasedAssetsGross
|
1450000 | USD |
| CY2011Q4 | us-gaap |
Capital Leased Assets Gross
CapitalLeasedAssetsGross
|
0 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
52825527 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
99901264 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
83255848 | USD |
| CY2009Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
67464506 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
47075737 | USD |
| CY2011 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-30430321 | USD |
| CY2010 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
15791342 | USD |
| CY2011Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
2730059 | shares |
| CY2011Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
112709174 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
103989272 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
112709174 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
103989272 | shares |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
112709 | USD |
| CY2011Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
103990 | USD |
| CY2012 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-53552002 | USD |
| CY2011 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-19769851 | USD |
| CY2010 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-53241650 | USD |
| CY2012 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk, Sources of Supply and Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to a significant concentration of credit risk consist of cash and cash equivalents and accounts receivable. We maintain our cash and cash equivalent balances with one major commercial bank. Deposits held with the bank exceed the amount of insurance provided on such deposits.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have license and collaborative agreements with pharmaceutical companies under which we receive payments for license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts at December 31, 2012 and 2011. Approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">86%</font><font style="font-family:inherit;font-size:10pt;"> of accounts receivable balance as of December 31, 2012 represents amounts due from Roche and Pfizer. Approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">82%</font><font style="font-family:inherit;font-size:10pt;"> of the accounts receivable balance as of December 31, 2011 represents amounts due from Roche, Baxter and ViroPharma. For the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012, 2011 and 2010</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">45%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">19%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">52%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues were from Roche and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">17%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues were from Baxter, respectively. For the year ended December 31, 2012, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues were from Pfizer. In addition, for the year ended December 31, 2011, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues were from ViroPharma and Intrexon, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide revenues from external customers for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012, 2011 and 2010</font><font style="font-family:inherit;font-size:10pt;"> consisted of domestic revenues of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$22.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$44.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and foreign revenues of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Of our total foreign revenues for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012, 2011 and 2010</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, were attributable to Switzerland. We attribute revenues under collaborative agreements to the individual countries where the collaborator is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. For the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012, 2011 and 2010</font><font style="font-family:inherit;font-size:10pt;">, we had no foreign based operations, and we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> long-lived assets located in foreign countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on two third-party manufacturers for the supply of the bulk formulation of rHuPH20 which is the active pharmaceutical ingredient (“API”) in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and each of our collaborators’ product candidates. Payments due to these suppliers represent </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">59%</font><font style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012 and 2011</font><font style="font-family:inherit;font-size:10pt;">, respectively. We also rely on a third-party manufacturer for the fill and finish of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product under a contract we entered in June 2011. Payments due to this supplier represent </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.7%</font><font style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012 and 2011</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> | |
| CY2012 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1094400 | USD |
| CY2010 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
985283 | USD |
| CY2011 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
257834 | USD |
| CY2012 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
95950672 | USD |
| CY2010 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
67881747 | USD |
| CY2011 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
75925377 | USD |
| CY2011Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
20839285 | USD |
| CY2012Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
21805273 | USD |
| CY2011Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
20093017 | USD |
| CY2011Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
17203480 | USD |
| CY2012Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
22580577 | USD |
| CY2012Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
26200662 | USD |
| CY2011Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
17789595 | USD |
| CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
25364160 | USD |
| CY2012Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
30000000 | USD |
| CY2012Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
338320 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
861879 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
802006 | USD |
| CY2012Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
43845983 | USD |
| CY2011Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
40883990 | USD |
| CY2011Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
4129407 | USD |
| CY2012Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
8891017 | USD |
| CY2011Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
36754583 | USD |
| CY2012Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
34954966 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
15338000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
17345000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
128443000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
107489000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
19270000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
20286000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
69912000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
86732000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
926000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
771000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
76000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
179000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2975000 | USD |
| CY2012 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2122000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
128443000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
107489000 | USD |
| CY2011 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
355000 | USD |
| CY2010 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
433000 | USD |
| CY2012 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
508000 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1095823 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1079424 | USD |
| CY2010 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1507925 | USD |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.48 | |
| CY2011 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| CY2010 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.56 | |
| CY2011Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.03 | |
| CY2011Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.04 | |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.05 | |
| CY2011Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.10 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.14 | |
| CY2010 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2011 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4053590 | USD |
| CY2011Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3223936 | USD |
| CY2012 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | USD |
| CY2010 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | USD |
| CY2011 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | USD |
| CY2010 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-13542 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
1566 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-7370 | USD |
| CY2011 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2010 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
20954000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
22469000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
9935000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-18102000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-6722000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-18208000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
2118000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
1293000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
1671000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1153000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3023000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3106000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
3731000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
3379000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
1016000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3263487 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
711777 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3437089 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-65803 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1915641 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
13440622 | USD |
| CY2011 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-17209561 | USD |
| CY2012 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
2961993 | USD |
| CY2010 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-2388641 | USD |
| CY2011 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
373841 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2103433 | USD |
| CY2010 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-966129 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4420646 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4611346 | USD |
| CY2010 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2147119 | USD |
| CY2012 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
28000 | USD |
| CY2011 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
63530 | USD |
| CY2012 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
59028 | USD |
| CY2010 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
49015 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
18875 | USD |
| CY2010 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2011Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
74794 | USD |
| CY2012Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
751378 | USD |
| CY2011Q4 | us-gaap |
Inventory Net
InventoryNet
|
567263 | USD |
| CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
2670696 | USD |
| CY2012Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
1127061 | USD |
| CY2011Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
201822 | USD |
| CY2011Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
290647 | USD |
| CY2012Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
792257 | USD |
| CY2010 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
875000 | USD |
| CY2011 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
166000 | USD |
| CY2012 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
134728397 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
65758545 | USD |
| CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
17301840 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
18946153 | USD |
| CY2011 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
54250334 | USD |
| CY2010 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
12728597 | USD |
| CY2012 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
39437784 | USD |
| CY2011Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
0 | USD |
| CY2012Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
29661680 | USD |
| CY2012Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | USD |
| CY2012Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
29661680 | USD |
| CY2012 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as diabetes, oncology and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. Our proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates which have been submitted for regulatory approval in the U.S. and/or Europe as well as several others at various stages of development. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, the use of terms such as "Halozyme," "we," "our," and "us" in these Notes to Consolidated Financial Statements refers to Halozyme Therapeutics, Inc.</font></div></div> | |
| CY2010 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
61823392 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
112817618 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4748612 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-828508 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1412585 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-646544 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-34350425 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-64329296 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-45385506 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-53552002 | USD |
| CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19769851 | USD |
| CY2010 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-53241650 | USD |
| CY2012Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14021119 | USD |
| CY2011Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5165193 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15119181 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20005846 | USD |
| CY2011Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
3116288 | USD |
| CY2011Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9635717 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4405856 | USD |
| CY2011Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18415615 | USD |
| CY2012 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | Segment |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-53625446 | USD |
| CY2010 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-54257632 | USD |
| CY2011 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19838941 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
10245000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1865000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
2126000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
2073000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
2049000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2052000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
80000 | USD |
| CY2012Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
27900000 | USD |
| CY2011Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
481365 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1506615 | USD |
| CY2011 | us-gaap |
Other Income
OtherIncome
|
5560 | USD |
| CY2010 | us-gaap |
Other Income
OtherIncome
|
966967 | USD |
| CY2012 | us-gaap |
Other Income
OtherIncome
|
14416 | USD |
| CY2012 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
8625 | USD |
| CY2011 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
828508 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1412585 | USD |
| CY2010 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | USD |
| CY2010 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1015982 | USD |
| CY2012 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
73444 | USD |
| CY2011 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
69090 | USD |
| CY2010Q4 | us-gaap |
Other Restructuring Costs
OtherRestructuringCosts
|
0 | USD |
| CY2010 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
646544 | USD |
| CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
12752888 | USD |
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8332242 | USD |
| CY2012 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
29660600 | USD |
| CY2011 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
0 | USD |
| CY2010 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
0 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
81476845 | USD |
| CY2010 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
59965059 | USD |
| CY2010Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
60000000 | USD |
| CY2012Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
81500000 | USD |
| CY2012 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1680173 | USD |
| CY2010 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1858333 | USD |
| CY2011 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
4748612 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7516951 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10381089 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3700462 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1771048 | USD |
| CY2012 | us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P3Y | |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
70044073 | USD |
| CY2010 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
51773504 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
57563470 | USD |
| CY2010Q4 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
|
0.25 | |
| CY2010 | us-gaap |
Restructuring Reserve Settled With Cash
RestructuringReserveSettledWithCash
|
1200000 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-245021646 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-298573648 | USD |
| CY2010 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
978000 | USD |
| CY2010 | us-gaap |
Revenues
Revenues
|
13624115 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
42325226 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
56086436 | USD |
| CY2011Q2 | us-gaap |
Revenues
Revenues
|
23188948 | USD |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
22942428 | USD |
| CY2012Q2 | us-gaap |
Revenues
Revenues
|
7757175 | USD |
| CY2012Q4 | us-gaap |
Revenues
Revenues
|
21793549 | USD |
| CY2011Q1 | us-gaap |
Revenues
Revenues
|
7543894 | USD |
| CY2012Q1 | us-gaap |
Revenues
Revenues
|
7440179 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
5334323 | USD |
| CY2011Q4 | us-gaap |
Revenues
Revenues
|
2411166 | USD |
| CY2010 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
895518 | USD |
| CY2012 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
2887442 | USD |
| CY2011 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
1836102 | USD |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
682522 | shares |
| CY2011 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
18104073 | USD |
| CY2010 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
15122960 | USD |
| CY2012 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
24812199 | USD |
| CY2010Q4 | us-gaap |
Severance Costs
SeveranceCosts
|
1300000 | USD |
| CY2010 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4866325 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5569899 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8348587 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | USD |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0280 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0115 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0255 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0080 | |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0139 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0114 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
260722 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5869784 | shares |
| CY2010Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7975365 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.59 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
593293 | shares |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
6.29 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
6.72 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
8.34 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1624768 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1215442 | shares |
| CY2010 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1332714 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
7400000 | USD |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6379867 | shares |
| CY2009Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7804266 | shares |
| CY2010Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.87 | |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.82 | |
| CY2009Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.73 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
6800000 | USD |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
3958125 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
5.34 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
7400000 | USD |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
6086988 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
6.49 | |
| CY2010 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.88 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.56 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.71 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
9.90 | |
| CY2010 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
5.94 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
7.79 | |
| CY2011 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y9M18D | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y7M6D | |
| CY2010 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y8M12D | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y6M | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P5Y1M6D | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y3M18D | |
| CY2012Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
7820000 | shares |
| CY2010Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
8300000 | shares |
| CY2010 | us-gaap |
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
|
120000 | shares |
| CY2011 | us-gaap |
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
|
347883 | shares |
| CY2011 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
120 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | USD |
| CY2011Q4 | halo |
Accrued Outsourced Research And Development Expenses Current
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent
|
1910273 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
|
3045540 | shares |
| CY2010 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
479093 | shares |
| CY2012 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
444637 | shares |
| CY2011 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
3137056 | shares |
| CY2010 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
59965059 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
81476845 | USD |
| CY2010 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
120 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
|
374195 | shares |
| CY2012 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1680173 | USD |
| CY2010 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1858213 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4748492 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10900116 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
48853719 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20351456 | USD |
| CY2009Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6903389 | USD |
| CY2012 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | USD |
| CY2010 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | USD |
| CY2011 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | USD |
| CY2012 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div></div> | |
| CY2011Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
100927402 | shares |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
105009189 | shares |
| CY2011Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
104393835 | shares |
| CY2011Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
103406407 | shares |
| CY2011Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
103406407 | shares |
| CY2011Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102671410 | shares |
| CY2011Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
100927402 | shares |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
103223352 | shares |
| CY2012Q4 | halo |
Accrued Outsourced Research And Development Expenses Current
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent
|
2223242 | USD |
| CY2012Q4 | halo |
Additional Achievement Of Development And Regulatory Milestones
AdditionalAchievementOfDevelopmentAndRegulatoryMilestones
|
84000000 | USD |
| CY2012Q4 | halo |
Additional Maximum Proceeds Receivable From Partner Of License And Collaborative Agreement Upon Achievement Of Clinical Development Milestones
AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones
|
58500000 | USD |
| CY2011 | halo |
Allocated Share Based Compensation Expense Per Share Basic And Diluted
AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted
|
0.05 | |
| CY2012 | halo |
Allocated Share Based Compensation Expense Per Share Basic And Diluted
AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted
|
0.08 | |
| CY2010 | halo |
Allocated Share Based Compensation Expense Per Share Basic And Diluted
AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted
|
0.05 | |
| CY2011 | halo |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
172438 | USD |
| CY2010 | halo |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-314747 | USD |
| CY2012 | halo |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
44895 | USD |
| CY2012Q4 | halo |
Long Term Debt Including Interest Gross
LongTermDebtIncludingInterestGross
|
38434522 | USD |
| CY2012Q4 | halo |
Long Term Debt Interest Gross
LongTermDebtInterestGross
|
8434522 | USD |
| CY2012Q4 | halo |
Long Term Debt Maturities Repayments In Next Twelve Months
LongTermDebtMaturitiesRepaymentsInNextTwelveMonths
|
2076250 | USD |
| CY2012Q4 | halo |
Long Term Debt Maturities Repayments In Year Five
LongTermDebtMaturitiesRepaymentsInYearFive
|
3483876 | USD |
| CY2012Q4 | halo |
Long Term Debt Maturities Repayments In Year Four
LongTermDebtMaturitiesRepaymentsInYearFour
|
11206507 | USD |
| CY2012Q4 | halo |
Long Term Debt Maturities Repayments In Year Three
LongTermDebtMaturitiesRepaymentsInYearThree
|
11206507 | USD |
| CY2012Q4 | halo |
Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
|
10461382 | USD |
| CY2012Q1 | halo |
Public Offering Price Per Share
PublicOfferingPricePerShare
|
10.61 | |
| CY2010Q3 | halo |
Public Offering Price Per Share
PublicOfferingPricePerShare
|
7.50 | |
| CY2012Q1 | halo |
Purchase Of Common Stock By Affiliates
PurchaseOfCommonStockByAffiliates
|
1360000 | shares |
| CY2012Q1 | halo |
Purchase Of Common Stock By Affiliates Amount
PurchaseOfCommonStockByAffiliatesAmount
|
14400000 | USD |
| CY2012Q4 | halo |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
|
2 | plan |
| CY2012 | halo |
Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent
|
0.10 | |
| CY2011 | halo |
Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent
|
0.10 | |
| CY2010 | halo |
Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent
|
0.10 | |
| CY2011 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
102566089 | shares |
| CY2010 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
94357695 | shares |
| CY2012 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
111077105 | shares |
| CY2012Q4 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
112323056 | shares |
| CY2012Q1 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
107589514 | shares |
| CY2012Q3 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
112305002 | shares |
| CY2012Q2 | halo |
Shares Used In Computing Basic And Diluted Net Loss Per Share
SharesUsedInComputingBasicAndDilutedNetLossPerShare
|
112063665 | shares |
| CY2010Q3 | halo |
Stock Issuance Option Issued To Underwriter
StockIssuanceOptionIssuedToUnderwriter
|
1245000 | shares |
| CY2010Q3 | halo |
Stock Issuance Option Issued To Underwriter Price Per Share
StockIssuanceOptionIssuedToUnderwriterPricePerShare
|
7.25 | |
| CY2010Q3 | halo |
Stock Issuance Option Issued To Underwriter Sale Of Stock Exercise Contingency
StockIssuanceOptionIssuedToUnderwriterSaleOfStockExerciseContingency
|
8300000 | shares |
| CY2012Q1 | halo |
Stock Issued During Period Shares New Issues To Underwriter
StockIssuedDuringPeriodSharesNewIssuesToUnderwriter
|
1020000 | shares |
| CY2012 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2012 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2012 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2012 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | |
| CY2012 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-12-31 | |
| CY2012 | dei |
Document Type
DocumentType
|
10-K | |
| CY2012 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001159036 | |
| CY2013Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
113122900 | shares |
| CY2012 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2012 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
| CY2012Q2 | dei |
Entity Public Float
EntityPublicFloat
|
784500000 | USD |
| CY2012 | dei |
Entity Registrant Name
EntityRegistrantName
|
HALOZYME THERAPEUTICS INC | |
| CY2012 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2012 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
Yes |
